Marshall Wace
IRD

Marshall Wace’s Opus Genetics IRD Stock Holding History

Marshall Wace’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
2,313,380
+2,155,732
+1,367% +$7.46M 0.01% 955
2025
Q4 		$317K Buy
+157,648
New +$320K ﹤0.01% 2428
2021
Q3 		– Sell
-329,131
Closed -$1.74M – 3507
2021
Q2 		$1.74M Buy
+329,131
New +$1.63M 0.01% 1500

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Marshall Wace's IRD Position: Q1 2026 in Review

Marshall Wace increased its Opus Genetics (IRD) stake by 1,367% in Q1 2026, buying an estimated $7.46M and bringing the position to 2,313,380 shares worth $10.5M. The position accounts for 0.01% of the portfolio, ranked #955.

Marshall Wace first reported a position in IRD in Q2 2021 and has held it in 3 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Marshall Wace held 2,313,380 shares of Opus Genetics worth $10.5M as of Q1 2026.
  • Marshall Wace bought 2,155,732 Opus Genetics shares in Q1 2026, an estimated $7.46M.
  • Opus Genetics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #955 holding.
  • Marshall Wace first reported a position in Opus Genetics in Q2 2021 and has held it in 3 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.